Administration of isothiocyanate (E-4IB) and cisplatin leads to altered signalling and lysosomal export in human ovarian carcinoma sensitiveand cisplatin-resistant cells

Neoplasma

Volumn 56, Issue 3, 2009, Pages 208-214

  Duraj, J ^a   Hunakova, L ^a   Bodo, J ^a   Jakubikova, J ^a   Chovancova, J ^a   Sedlak, J ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Apoptosis; Cisplatin (CDDP); Cisplatin (CDDP) resistance; Isothiocyanate E 4IB; Lysosomes exosomes; Ovarian carcinoma cells

Indexed keywords

CISPLATIN; DYE; ETHYL 4 ISOTHIOCYANATOBUTANOATE; ISOTHIOCYANIC ACID; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ISOTHIOCYANIC ACID DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYSOSOME; OVARY CARCINOMA; STAINING; WESTERN BLOTTING; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ISOTHIOCYANATES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LYSOSOMES; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85047681456     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_03_208     Document Type: Article

References (45)

1. Kollmannsberger C, Nichols C, Bokemeyer C. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer. 2006; 106: 1217-1226. doi:10.1002/cncr.21742 (Pubitemid 43363897)
2. Fink D, Nebel S, NORRIS PS et al. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br J Cancer 1998; 77:703-708. (Pubitemid 28077456)
3. GATELY DP, HOWELL SB. Cellular accumulation of the anticancer agent cisplatin:.Br J Cancer 1993; 67: 1171-1176.
4. CHOI MK, KIM DD. Platinum transporters and drug resistance. Arch Pharm. Res 2006; 29: 1067-1073. doi:10.1007/ BF02969293
5. Safaei R, HOWELL SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 2005; 53: 13-23. doi:10.1016/j.critrevonc. 2004.09.007 (Pubitemid 39656107)
6. PASETTO LM, D'ANDREA MR, BRANDES AA et al. The development of platinum compounds and their possible combination. Crit Rev Oncol Hematol 2006; 60: 59-75. doi:10.1016/j.critrevonc.2006.02.003
7. Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007; 251: 1-16. doi:10.1016/j.canlet.2006.10.007 (Pubitemid 46589761)
8. Wada T, PENNINGER JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838-2849. doi:10.1038/sj.onc.1207556 (Pubitemid 38638846)
9. Mansouri A, RIDGWAY LD, KORAPATI AL et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003; 278: 19245-19256. doi:10.1074/jbc.M208134200 (Pubitemid 36799316)
10. Safaei R, Katano K, LARSON BJ et al. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin Cancer Res 2005; 11:756-767. (Pubitemid 40116905)
11. Denzer K, KLEIJMEER MJ, HEIJNEN HF et al. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000; 113: 3365-3374. (Pubitemid 30831289)
12. CHAUHAN SS, LIANG XJ, SU AW et al. Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br J Cancer 2003; 88: 1327-1334. doi:10.1038/sj.bjc.6600861 (Pubitemid 36606353)
13. Bursch W, Hochegger K, Torok L et al. Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments. J Cell Sci 2000; 113: 1189-1198. (Pubitemid 30229536)
14. Safaei R, LARSON BJ, CHENG TC et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 2005; 4: 1595-1604. doi:10.1158/1535-7163. MCT-05-0102 (Pubitemid 41556443)
15. Gamet-Payrastre L, Li P, Lumeau S et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 2000; 60: 1426-1433. (Pubitemid 30152017)
16. Miyoshi N, Takabayashi S, Osawa T et al. Benzyl isothiocyanate inhibits excessive superoxide generation in inflammatory leukocytes: implication for prevention against inflammation-related carcinogenesis. Carcinogenesis 2004; 25: 567-575. doi:10.1093/carcin/bgh051 (Pubitemid 38499945)
17. PULLAR JM, THOMSON SJ, KING MJ et al. The chemopreventive agent phenethyl isothiocyanate sensitizes cells to Fas-mediated apoptosis. Carcinogenesis 2004; 25: 765-772. doi:10.1093/carcin/bgh063 (Pubitemid 38618529)
18. CHEN YR, WANG W, KONG AN et al. Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. J Biol Chem 1998; 273: 1769-1775. doi:10.1074/jbc.273.3.1769
19. Xiao D, SINGH SV. Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res 2002; 62: 3615-3619. (Pubitemid 34728834)
20. Floch L, Kuban J, Gogova A et al. Synthesis of ethyl 4- isothiocyanatobutanoate derivatives. Chem Pap -Chem zvesti 1997; 51: 416-420.
21. Bodo J, Hunakova L, Kvasnicka P et al. Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterations. Br J Cancer 2006; 95: 1348-1353. doi:10.1038/sj.bjc.6603434 (Pubitemid 44760084)
22. Bodo J, Chovancova J, Hunakova L et al. Enhanced sensitivity of human ovarian carcinoma cell lines A2780 and A2780/ CP to the combination of cisplatin and synthetic isothiocyanate ethyl 4-isothiocyanatobutanoate. Neoplasma 2005; 52: 510-516. (Pubitemid 41809411)
23. Katano K, Safaei R, Samimi G et al. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin Cancer Res 2004; 10: 4578-4588. doi:10.1158/1078-0432. CCR-03-0689 (Pubitemid 38878902)
24. Wu H, Cao Y, Weng D et al. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett 2008 [Epub ahead of print].
25. Gagnon V, Mathieu I, Sexton E et al. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 2004; 94: 785-795. doi:10.1016/j.ygyno.2004.06.023 (Pubitemid 39194476)
26. ESKELINEN EL, TANAKA Y, SAFTIG P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol 2003; 13: 137-145. doi:10.1016/S0962-8924(03)00005-9
27. BEALE PJ, ROGERS P, BOXALL F et al. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer 2000; 82: 436-440. doi:10.1054/ bjoc.1999.0939
28. Yu L, Wang z. Difference in expression of Bcl-2 and Bcl-xl genes in cisplatin-sensitive and cisplatin-resistant human in ovarian cancer cell lines. J Huazhong Univ Sci Technol Med Sci 2004; 24:151-153. (Pubitemid 41559658)
29. Williams J, LUCAS PC, GRIFFITH KA, et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005; 96: 287-295. doi:10.1016/j.ygyno.2004.10.026 (Pubitemid 40127123)
30. Siddik Zh. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279. doi:10.1038/sj.onc.1206933
31. Sharma H, Sen S, Lo Muzio L et al. Antisense mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther 2005; 4: 720-727. (Pubitemid 41351170)
32. Dong z, Wang J. Hypoxia selection of death-resistant cells. A role for Bcl-X(L). J Biol Chem 2004; 279: 9215-9221. doi:10.1074/jbc.M312225200
33. CHO HJ, KIM JK, KIM KD et al. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 2006; 237: 56-66. doi:10.1016/j.canlet.2005.05.039
34. Notarbartolo M, Cervello M, Poma P et al. Expression of the IAPs in multidrug resistant tumor cells. Oncol Rep 2004; 11: 133-136.
35. Nomura T, Yamasaki M, Nomura Y et al. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 2005; 14: 993-997.
36. Wang z, Xie Y, Wang H. Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther 2005; 4: 716-719.
37. PARK SA, PARK HJ, LEE BI et al. Bcl-2 blocks cisplatininduced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res Mol Brain Res 2001; 93: 18-26. doi:10.1016/S0169-328X(01)00176-0
38. Kim JK, Kim KD, Lee E et al. Up-regulation of Bfl-1/A1 via NF kappaB activation in cisplatin-resistant human bladder cancer cell line. Cancer Lett 2004; 212: 61-70. doi:10.1016/j. canlet.2004.02.021 (Pubitemid 38887721)
39. UPADHYAY AK, SINGH S, CHHIPA RR et al. Methyl-beta- cyclodextrin enhances the susceptibility of human breast cancer cells to carboplatin and 5-fluorouracil: involvement of Akt, NF-kappaB and Bcl-2. Toxicol Appl Pharmacol 2006; 216: 177-185. doi:10.1016/j.taap.2006.05.009
40. Venkatraman M, ANTO RJ, NAIR A et al. Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinogen 2005; 44: 51-59. doi:10.1002/mc.20116 (Pubitemid 41216407)
41. Poma P, Notarbartolo M, Labbozzetta M et al. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int J Oncol 2006; 28: 923-930.
42. Strozyk E, Poppelmann B, Schwarz T et al. Differential effects of NF-kappaB on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome. Oncogene 2006; 25: 6239-6251. doi:10.1038/ sj.onc.1209655 (Pubitemid 44564741)
43. KIM SB, KIM JS, LEE JH et al. NF-kappaB activation is required for cisplatin-induced apoptosis in head and neck squamous carcinoma cells. FEBS Lett 2006; 580: 311-318. doi:10.1016/j.febslet.2005.12.012
44. Li F, Meng L, zhou J et al. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1. Biochem Biophys Res Commun 2005; 335: 1070-1077. doi:10.1016/j.bbrc. 2005.07.169
45. Hövelmann S, BECKERS TL, SCHMIDT M. Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells. Br J Cancer 2004; 90: 2370-2377. (Pubitemid 38961902)